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ABSTRACT: Spider venom toxins, such as Protoxin-II
(ProTx-II), have recently received much attention as selective
Nav1.7 channel blockers, with potential to be developed as
leads for the treatment of chronic nocioceptive pain. ProTx-II
is a 30-amino acid peptide with three disulﬁde bonds that has
been reported to adopt a well-deﬁned inhibitory cystine knot
(ICK) scaﬀold structure. Potential drawbacks with such
peptides include poor pharmacodynamics and potential
scrambling of the disulﬁde bonds in vivo. In order to address
these issues, in the present study we report the solid-phase
synthesis of lanthionine-bridged analogues of ProTx-II, in
which one of the three disulﬁde bridges is replaced with a
thioether linkage, and evaluate the biological properties of
these analogues. We have also investigated the folding and disulﬁde bridging patterns arising from diﬀerent methods of oxidation
of the linear peptide precursor. Finally, we report the X-ray crystal structure of ProTx-II to atomic resolution; to our knowledge
this is the ﬁrst crystal structure of an ICK spider venom peptide not bound to a substrate.
■ INTRODUCTION
Peptide toxins hold considerable promise as novel therapeutics
due to the potency and speciﬁcity with which they interact with
their biological targets, low cost of synthesis, and largely well-
understood metabolic pathways.1 These peptides are often
cysteine-rich and contain intricate disulﬁde bonding patterns
that are crucial for their biological activity.2 Despite these
encouraging properties, however, to date only one peptide
toxin-based therapeutic (Ziconitide, marketed as Prialt) has
been approved for clinical use.3 This is largely due to
commonly encountered problems in the in vivo stability of
peptide toxins. Poor transport across the intestinal wall and
susceptibility to enzymatic degradation mean that peptide
toxins are not often suitable for oral administration and must be
administered by intrathecal injection.3 Poor pharmacodynamics
proﬁles are also an issue: none of these peptide toxins can cross
the blood-brain or blood-nerve barriers easily.4 In addition,
many toxins still show a lack of receptor subtype selectivity,
leading to undesired side eﬀects.5 Finally, the disulﬁde bonds in
these toxins are susceptible to reduction in extracellular
environments, by glutathione and disulﬁde bond isomerases,
leading to chain unfolding and oxidative refolding with
consequent loss of biological activity.6 Considerable eﬀorts
have therefore been directed toward developing replacements
for the disulﬁde bonds in peptide toxins that are not susceptible
to reduction or oxidative refolding. One of the earliest methods
employed was the use of diselenide bonds, which have only
slight steric diﬀerences to the native disulﬁde bond.6 Further
studies showed that the diselenide analogues did not undergo
reduction in blood plasma and actually showed slightly
improved potency over the native structure.7 Both unsatu-
rated8,9 and saturated10 dicarba-bridges have also been used as
disulﬁde bond replacements in cystine-rich toxins, using either
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ring-closing metathesis8,9,11 or solid-phase peptide synthesis
(SPPS) using diﬀerentially protected diamino diacids10 as the
synthetic strategy. These disulﬁde bond replacements resulted
in peptide toxin analogues of comparable potency,8 and in
some cases replacing diﬀerent cystine bridges can enable the
resulting toxin analogue to be tuned to one or other of two
possible receptor targets.9 Lactam bridges12 and cystathione
analogues13 have also been employed to stabilize the structure
and modulate the activity of peptide toxins with multiple
cystine bridges, with varying impact on receptor antagonism
depending on the geometry of the replacement and which of
the disulﬁde linkages has been replaced. Carba-,14,15 cystathio-
nine-,16 and triazole-bridged17 analogues of other disulﬁde-
bridged biologically active peptides have also been synthesized,
again with varying eﬀects on the biological properties of these
peptide analogues. Surprisingly, lanthionine-bridged analogues
of peptide toxins have not previously been studied.
Replacement of cystine by lanthionine results in a thioether
side-chain bridge that cannot be cleaved in vivo. This linkage is
one bond shorter than a cystine-bridged peptide and will have
diﬀerent conformational preferences. However, replacement of
cystine with lanthionine has been carried out with other
bioactive peptides such as enkephalin18 and sandostatin19 and
has led to potent analogues of these peptides, as has
replacement of cystine with selenolanthionine in oxytocin
analogues.20
In previous work, we have developed solid-phase methods
for synthesizing lanthionine-containing peptides, using orthog-
onally protected lanthionine,21 which have enabled the
synthesis of a range of lantibiotics and analogues,22,23 including
Lactocin S24 and Lacticin 3147.25 Looking to extend our
methodology for incorporating lanthionine bridges into
peptides, we elected to attempt to synthesize lanthionine-
containing analogues of ProTx-II, a peptide isolated from the
venom of the Peruvian green velvet tarantula (Thrixopelma
puriens).26 ProTx-II belongs to a family of spider peptide toxins
that contain six cysteine residues. These are oxidized to form
three interlinked disulﬁde bonds, connected together in a 1-4,
2-5, and 3-6 pattern referred to as the inhibitory cystine knot
(ICK) scaﬀold. Other examples of toxins sharing the same
pattern include HwTx-IV,27 GpTx-I,28 and CcoTx-I29 (Figure
1). The ICK scaﬀold has at its core an antiparallel beta-sheet
comprising two or three strands, with a third disulﬁde bridge
inserted between the loop formed by the ﬁrst two disulﬁde
bridges. The number and sequence of amino acids between the
cysteine residues are highly variable in these ICK peptides,
leading to a wide variety of secondary structural motifs and
peptide sequences being displayed between each disulﬁde
bridge.30,31 Eﬀective synthetic routes to ICK peptides with
disulﬁde bond replacements are therefore of considerable
interest in the development of peptide toxins with in vivo
stability and have the potential to ﬁne-tune receptor selectivity.
ProTx-II has been the subject of particular interest from
researchers as a possible lead for the treatment of chronic
nociceptive pain.4 It has been reported to have both the highest
potency against the voltage-gated ion channel Nav1.7 (IC50 0.3
nM) and exceptional receptor subtype selectivity (100-fold
more selective for the Nav1.7 ion channel compared with other
sodium ion channel subtypes).32 Nav1.7 has been implicated as
a target for the treatment of chronic pain after loss-of-function
mutations in the corresponding SCN9A gene left their carriers
unable to feel pain, with seemingly no other detrimental eﬀects
on their health.33 By contrast, gain-of-function mutations on
the same gene cause suﬀerers to feel a constant burning
sensation, usually in their hands and feet.34 Recently, the NMR
structure of ProTx-II and analogues has been solved (PDB ID:
2N9T).35 Park and co-workers have also elucidated the solution
structure of ProTx-II by NMR,36 and both structures show that
the peptide adopts a classical ICK knot structure with a
conformationally labile region at the C-terminus.
Despite these structural studies, much remains unknown
about the mechanism of action of ProTx-II on Nav1.7.
Structural and mutagenesis investigations of the interaction of
ProTx-II with the Nav1.5 ion channel established that ProTx-II
does not act by blocking the channel pore.37 Instead, studies
into the interaction of ProTx-II and HwTx-IV with hNav1.7
proposed that both peptides interact with the domain II
voltage-sensing domain (VSD), with ProTx-II also trapping the
domain IV VSD in the resting conﬁguration.38 Mutagenesis
experiments on ProTx-II by Park and co-workers,36 and
investigations of chimeric peptides incorporating sequences
from the related toxin PaTx-I, have revealed that the C-terminal
domain is especially important for the speciﬁcity and potency of
its interaction with Nav1.7, and that certain C-terminal
modiﬁcations can improve the potency relative to the wild-
type (wt) peptide. Henriques and co-workers35 noted that
ProTx-II potency is correlated with its membrane-binding
ability, and they established the importance of certain residues
in the main body of the peptide in binding to membranes.
Based on these results, they proposed a model for ProTx-II
inhibition of Nav1.7 where binding to the membrane orientates
the peptide, which allows for the C-terminal domain to interact
with the VSD of Nav1.7. Recently, Flinspach and co-workers
39
identiﬁed JNJ63955918, a potent and selective inhibitor of
Nav1.7, from a library of over 1500 peptides generated using
ProTx-II as a scaﬀold, and Deuis and co-workers have
characterized the mode of action of another highly selective
hNav1.7 ICK spider venom peptide, Pn3a.
40 While these studies
have considerably advanced our understanding of ProTx-II
inhibition of Nav1.7, we do not yet have a comprehensive
understanding of the binding mode of ProTx-II, or how
inhibition of Nav1.7 relates to analgesia: injections of ProTx-II
failed to elicit analgesia in a mouse model.4 Further studies
relating the structure and function of ProTx-II are therefore
vital in elucidating its mechanism of action, which will be key to
designing future eﬀective treatments for chronic pain.
Figure 1. Amino acid sequences and disulﬁde bond connectivities of
the ICK scaﬀold peptides ProTx-II, HwTx-IV, PaTx-1, GpTx-I,
CcoTx-I, and Prialt.
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Our goal in this research was to use and extend our solid-
phase synthesis methodology to prepare lanthionine-bridged
analogues of ProTx-II and of individual rings of ProTx-II. We
sought to explore the eﬀects of subtle changes in peptide
conformation arising from replacing each of the naturally
occurring disulﬁde bridged rings in turn with a thioether linked
ring on the binding of these peptides to hNav1.7 ion channels
in vitro using patch-clamp assays. As part of this study, we have
also investigated the eﬀects of using diﬀerent oxidative folding
methods on the disulﬁde connectivity of the wt peptide
sequence and their consequences for the biological activity of
ProTx-II. Finally, we report the high-resolution X-ray crystal
structure of wt ProTx-II.
■ RESULTS AND DISCUSSION
Synthesis of (2R,6R)-(Allyl, Aloc/Fmoc)-Lanthionine
(1). In the naturally occurring lantibiotics, the lanthionine
residues are present as the meso-(2R,6S) diastereoisomer.
However, in ProTx-II all the constituent amino acids, including
the Cys residues, are the naturally occurring L-enantiomers. In
order to synthesize analogues of ProTx-II with the Cys-Cys
bridges replaced by lanthionine bridges with the same
stereochemistry, we adapted our previously published proce-
dure21 to give the key orthogonally protected (R,R)-lanthionine
building block 1. Minor modiﬁcations to the original synthetic
methodology were made in order to scale up the procedure to
give multigram quantities of 1 (Supporting Information).41
Synthesis of Single Ring Truncated Analogues of
ProTx-II Containing Thioether or Disulﬁde Bridges.
Figure 2. Single ring thioether and disulﬁde analogues of ProTx-II. The positions of the Cys groups, and their Met replacements, are marked
according to the numbering from the full-length wt ProTx-II sequence.
Scheme 1. Synthesis of Lanthionine-Bridged Peptide 2aa
aReagents and conditions: (i) (allyl, Aloc/Fmoc)-lanthionine 1, PyAOP, HOAt, DIPEA, DMF, μwave, 5 min, 60 °C; (ii) incorporation of standard
protected amino acids with HBTU, DIPEA, DMF, followed by deprotection with piperidine; (iii) Pd(PPh3)4, 1,3-dimethylbarbituric acid, DMF,
CH2Cl2, then 40% piperidine/DMF; (iv) PyAOP, HOAt, DIPEA, DMF, μwave, 5 min, 60 °C; (v) Fmoc-Lys(Boc)-OH, HBTU, DIPEA, DMF, then
20% piperidine/DMF; (vi) TFA, ethanedithiol, iPr3SiH, H2O.
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Before embarking on the synthesis of complex cystine knot
structures containing both disulﬁde and thioether linkages, we
elected to synthesize analogues of individual rings of ProTx-II,
incorporating either thioether or disulﬁde bridges (Figure 2).
Previous work in our group21 and by others24,25 has enabled
cyclic lanthionine-bridged peptides with up to nine residues in
the ring to be synthesized using this solid-phase approach. We
envisaged that some development of the methodology would
be needed to access lanthionine-bridged analogues of ProTx-II
with up to 13 residues in the ring. Moreover, producing smaller
fragments of ProTx-II would enable us to determine whether
any biological activity would remain in the individual rings once
removed from the highly ordered framework of the ICK
structure.
Indeed, a trial synthesis of the C-terminal ring 2a using
standard peptide coupling conditions at room temperature
revealed problems. Linear peptide 6 was prepared on a low-
loading NovaSyn TGT resin, and lanthionine derivative 1 was
then coupled using PyAOP, HOAt, and DIPEA to give 7. This
was then elongated to give the linear peptide 8 (Scheme 1).
We then envisaged chemoselective removal of the allyl and
Aloc groups, followed by Fmoc deprotection, cyclization on-
resin, installation of the ﬁnal amino acid, and cleavage from
resin. However, this synthetic sequence yielded only small
amounts of the desired 2a, mixed with linear peptide
byproducts in which the lanthionine residue had not been
incorporated. We therefore investigated conditions for the
incorporation of 1 using microwave irradiation coupling
conditions.41 Coupling with PyAOP/HOAt/DIPEA using
microwave irradiation at 300 W and 60 °C for 5 min proved
to be optimal for incorporating 1 to give resin-bound
intermediate 7. Standard SPPS was then used to elongate this
to give resin-bound peptide 8. The allyl and Aloc groups were
then selectively removed with Pd(PPh3)4 using 1,3-dimethyl-
barbituric acid as an allyl group scavenger;42,43 subsequent
removal of the Fmoc group gave 9. This was then selectively
cyclized on-resin with PyAOP/HOAt/DIPEA,44 again using
microwave irradiation at 300 W and 60 °C for 5 min. Chain
extension of 10 to give 11 was followed by resin cleavage to
give analogue 2a. Using this approach, we also synthesized a
second analogue, 3a, as it has recently been shown36 that the
ﬂexible C-terminal fragment of ProTx-II is important for both
potency and sodium channel selectivity. Pleasingly, we were
also able to prepare the lanthionine analogue of the larger (13
residues) central ring, 4a. However, unfortunately the largest
(15 residues) ring, 5a, could not be synthesized. For
comparison purposes, the Cys-linked disulﬁde analogues 2b,
3b, 4b, and 5b were also synthesized. In each case the linear
peptides were prepared using standard techniques (Supporting
Information) and then cyclized by stirring for 10 days at 4 °C in
water, giving the desired peptides in good yield and purity.
Synthesis of Full-Length ProTx-II Analogues with One
Disulﬁde Bridge Replaced by a Thioether Bridge. Having
successfully prepared the single ring analogues, we turned our
attention to the full length analogues 12, 13, and 14 (Figure 3).
Our strategy for these peptides had to take into account two
possible challenges. The ﬁrst is that the thioether bridges in
lantibiotics are very susceptible to aerial oxidation,45 and
therefore prolonged reaction times when forming the Cys-Cys
bridges should be avoided. The second problem that we
anticipated, in particular after the formation of the lanthionine
bridge, was the folding or aggregation of the resin-bound
Figure 3. Lanthionine-bridged analogues of ProTx-II.
Scheme 2. Synthesis of Lanthionine-Bridged ProTx-II Analogue 12a
aStandard protecting groups were used for the amino acids, with additional Hmb protection as indicated; see Experimental Section. Reagents and
conditions: (i) 1, PyAOP, HOAt, DIPEA, DMF, μwave, 5 min, 60 °C; (ii) incorporation of standard protected amino acids with HBTU, DIPEA,
DMF, followed by deprotection with piperidine; (iii) 40% piperidine/DMF, then Pd(PPh3)4, 1,3-dimethylbarbituric acid, DMF, CH2Cl2; (iv)
PyAOP, HOAt, DIPEA, DMF, μwave, 5 min, 60 °C; (v) incorporation of standard protected amino acids with HBTU, DIPEA, DMF, followed by
deprotection with piperidine; (vi) TFA, iPr3SiH, H2O.
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peptide during synthesis, resulting in the N-terminal amino acid
becoming inaccessible to subsequent activated amino acids. In
the event this proved to be a more serious problem. Attempted
solid-phase synthesis of the linear peptides failed in each case
shortly after incorporation of the ﬁrst lanthionine residue, even
when microwave coupling conditions were used, resulting in
the isolation of short peptides of between 6 and 12 residues. In
order to circumvent this problem, we inserted Hmb-protected
amino acids at positions 4, 14, 18, 23, and 28, in order to
disrupt hydrogen bonding and prevent on-resin aggregation.46
For analogue 12, we also elected to use the same protecting
groups for the Cys residues at positions 2, 9, 16, and 21. We
anticipated that the presence of the thioether bridge between
positions 15 and 25 would enable the peptide to fold correctly
and the Cys-Cys bridges to be formed with the correct
connectivity, without the need for an orthogonal Cys side-chain
protecting strategy. Thus, (Scheme 2) protected lanthionine 1
was coupled to the resin-bound peptide 15 using the
microwave conditions optimized for the single ring analogues.
Chain extension of 16 using standard coupling conditions, and
Hmb-protected amino acids as indicated, aﬀorded 17. The
lanthionine bridge was then formed by sequential removal of
the Fmoc and allyl/Aloc protecting groups, followed by
microwave-assisted cyclization on-resin, as before.
Chain extension of 18 gave the fully protected, resin-bound
peptide intermediate 19. Subsequent cleavage of 19 from the
resin, using a deprotection cocktail lacking EDT, gave the
desired fully deprotected and cyclized peptide 12 (overall yield
0.4% after puriﬁcation). This suggests that the partly folded,
lanthionine-bridged structure does indeed aid the cyclization of
the disulﬁde bonds during the cleavage and deprotection
procedure. The same strategy was used to synthesize 14 in a
yield of 1.1% after puriﬁcation.
For analogue 13, as the third and fourth cysteine residues are
next to each other in this sequence, we decided to employ
orthogonal protecting group chemistry in order to guarantee
the 1-4, 3-6 connectivity. We elected to use S(Tmp)-protected
cysteine47 as this protecting group is stable to piperidine but
very labile under mild thiolysis conditions, for example in the
presence of DTT. Thus, (Scheme 3) 1 was coupled to linear
resin-bound peptide 20 using microwave coupling conditions to
give 21, and chain extension as before aﬀorded 22.
Deprotection of Fmoc and allyl/Aloc protecting groups,
followed by microwave-assisted cyclization on-resin, gave 23,
which was again chain-extended to give the resin-bound peptide
24. On-resin cleavage of the Tmp protecting groups with DTT
was followed by oxidation with NCS to give the bicyclic resin-
bound peptide 25. Cleavage and deprotection using the same
deprotection cocktail, lacking EDT, followed by stirring in
water at 4 °C, gave the desired tricyclic peptide 13 in 7% yield
after puriﬁcation.
As a control for the biological testing, we also synthesized the
parent ProTx-II structure. The linear sequence was prepared
using standard SPPS protocols (Supporting Information) and
puriﬁed. Despite reports of racemization of cysteine residues
under these conditions,48 substitution of DIPEA as the base in
the coupling step with 2,4,6-collidine did not noticeably
improve the purity of the crude linear ProTx-II produced.
Although formation of the correct connectivity of the three
disulﬁde bonds in these toxins is clearly crucial for folding of
the peptide into the biologically active structure, achieving
regioselective disulﬁde bond formation is diﬃcult to achieve
using orthogonal protecting groups for three pairs of Cys
Scheme 3. Synthesis of Lanthionine-Bridged ProTx-II Analogue 13a
aStandard protecting groups were used for the amino acids, with additional Hmb protection as indicated; see Experimental Section. Reagents and
conditions: (i) 1, PyAOP, HOAt, DIPEA, DMF, μwave, 5 min, 60 °C; (ii) incorporation of standard protected amino acids with HBTU, DIPEA,
DMF, followed by deprotection with piperidine; (iii) 40% piperidine/DMF, then Pd(PPh3)4, 1,3-dimethylbarbituric acid, DMF, CH2Cl2; (iv)
PyAOP, HOAt, DIPEA, DMF, μwave, 5 min, 60 °C; (v) incorporation of standard protected amino acids with HBTU, DIPEA, DMF, followed by
deprotection with piperidine; (vi) 5% DTT in 0.1 M NMM, DMF; (vii) NCS (2 equiv), DMF; (viii) TFA, iPr3SiH, H2O.
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residues.49 Conotoxins with three disulﬁde bridges are typically
synthesized as a linear precursor with all six cysteines
unprotected, and then diﬀerent oxidation methods are
attempted until the correct topology is formed. The wide
variation in peptide sequence has precluded the development of
a single, general method for such cyclizations.50 Intriguingly, in
some cases oxidative folding of linear conotoxin precursors has
resulted in two disulﬁde isoforms, both of which have potent
Nav channel blocking activity.
51 However, for this family of
spider toxins there are no reports comparing the eﬀectiveness
and selectivity of diﬀerent oxidative cyclization methods. Initial
attempts to cyclize the linear, unprotected ProTx-II peptide
sequence using the conditions reported by Middleton26 were
unsuccessful in our hands. We next turned to aerobic
oxidation,49 and after some investigation we determined that
the puriﬁed, unprotected linear ProTx-II peptide could be
cyclized in H2O at 10 °C and a concentration of 0.1 mg/mL
over 7 days to give the cyclized peptide (ProTx-II/7d) cleanly
and in high yield. For comparison, ProTx-II was prepared using
the conditions recently described by Park and co-workers.36 In
this procedure, the unpuriﬁed, unprotected linear ProTx-II
peptide was stirred at pH 8 in a mixture of glutathione (GSH),
glutathione disulﬁde (GSSG), urea, and Tris-HCl for 24 h,
followed by adjustment to pH 3 and puriﬁcation of the peptide
by HPLC to yield the cyclic peptide (ProTx-II/24h). As
additional controls, we also purchased commercial samples of
ProTx-II from two companies, Sigma-Aldrich and Smartox.
Biological Activity of ProTx-II and Analogues. All
compounds were tested against stably transfected cell lines
expressing the hNav1.7 receptor, using the hNav1.7-HEK cell
IonWorks Population Patch Clamp Assay (Essen) and the
QPatch Patch Clamp Assay (B’SYS GmbH). Perhaps
unsurprisingly, neither the single ring lanthionine analogues
2a−4a, nor their Cys-Cys counterparts 2b−5b, showed any
activity in these assays. Disappointingly, the full-length
lanthionine bridged analogues 12, 13, and 14 did not show
any activity either. Finally, to our surprise, the wt ProTx-II/7d
that we had synthesized was completely inactive, as was the
sample purchased from Sigma-Aldrich, whereas the ProTx-II/
24h sample, and the sample from Smartox, showed the
expected activity (Supporting Information).
Disulﬁde Connectivity and Conformation of wt ProTx-
II Prepared by Diﬀerent Oxidative Folding Methods.
Liquid chromatography−mass spectrometry (LC-MS) showed
that all four samples of wt ProTx-II had the correct amino acid
composition and initially appeared to indicate that all three
disulﬁde bonds had formed in each sample. The peptide
samples were then compared by HPLC, and a clear diﬀerence
was seen between the retention times of the ProTx-II/7d and
the ProTx-II/24h peptides; this was veriﬁed by co-injection of
the two samples (Figure 4).
This was further conﬁrmed by comparing the HPLC trace of
the ProTx-II/24h peptide with the Smartox sample (Support-
ing Information Figure S1b) and the ProTx-II/7d peptide with
the Sigma sample (Supporting Information Figure S1c). This
strongly suggested that the ProTx-II/24h peptide had either a
diﬀerent conformation or diﬀerent disulﬁde bond connectivity
to the ProTx-II/7d peptide.
Investigation of Disulﬁde Bond Connectivities of the
ProTx-II Peptides by Mass Spectrometry. We reasoned
that the diﬀerences in biological activity and HPLC retention
time might arise from diﬀerences in disulﬁde bond connectivity
between the two groups of peptides. In particular, because the
Cys residues at positions 15 and 16 are adjacent, it was
conceivable that one group of peptides might have the 1-4, 2-5,
and 3-6 connectivity pattern observed for ICK knot peptides,
and the other group might have a diﬀerent connectivity, such as
the 1-3, 2-5, and 4-6 pattern observed in spider toxins such as
huwentoxin-II (HwTx-II).52 To investigate this possibility,
proteolytic digestion of the peptide samples, followed by
sequencing of the resulting products by mass spectrometry, was
attempted following the method of Middleton et al.26 In our
hands, however, the sequencing experiments could not be
reproduced, and enzymatic digestion did not conclusively
determine the disulﬁde bond connectivity.
We therefore decided to examine in more detail the intact
forms of the peptide by means of nano-electrospray ionization
(nanoESI) and ion mobility mass spectrometry (IM-MS). IM-
MS can separate ions based on their mass, charge, and overall
shape and has been successfully used to separate peptides of the
same sequence but diﬀering modiﬁcation states.53,54 We
hypothesized that any diﬀerences observed in the IM-MS
data between these two peptides were likely to be due to
diﬀerences in shape, which could in turn be caused by
diﬀerences in disulﬁde bond connectivity. The nanoESI spectra
of ProTx-II/24h and ProTx-II/7d samples are shown in
Figure 5. The charge state distribution diﬀers between the two
samples, with the ProTx-II/24h exhibiting an overall lower
charge state which is indicative of a more folded structure.55
A closer inspection of the +4 charge state from both peptides
revealed diﬀerences in the isotopic distribution (Figure 6). We
simulated the theoretical isotopic distribution for a ProTx-II
peptide which would be either fully oxidized or fully reduced.
Comparison of the experimental and theoretical isotope
distributions revealed that, while the ProTx-II/24h sample
corresponds to a peptide with all cysteines oxidized, the ProTx-
II/7d appears to be a mixture of oxidized and fully reduced
species. To probe this even further we carried out IM-MS
analyses of the +4 charge state. Figure 7 shows the arrival time
distributions (ATDs) for the two peptides. While the ATD of
ProTx-II/24h comprises one peak, the same is not true for the
ProTx-II/7d peptide. The ATD for the ProTx-II/7d peptide is
broad and consists of more than one peak, signifying the
existence of multiple diﬀerent species being present.
Reconstructing the mass spectra that correspond to each
region of the ATD for the ProTx-II/7d sample, further reveals
that none of these co-existing forms of this peptide are in the
fully oxidized state as indicated by the isotopic ratio.
Our native and IM-MS studies, therefore, show that the two
peptides diﬀer in the extent of disulﬁde bond formation, and
this may be responsible for the diﬀerence in activity against the
target sodium channel.
Figure 4. HPLC of ProTx-II/24h and ProTx-II/7d peptides. All
experiments were run using analytical HPLC Method B.
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Crystal Structure of ProTx-II. To conﬁrm the disulﬁde
bond connectivity of the biologically active ProTx-II, we
investigated its structure by X-ray crystallography. The
structures of spider venom peptides have generally been
studied to date by NMR; this is because their relatively small
size makes solving the structure by this method feasible, but is
also due to the reported diﬃculty in growing suitable crystals
for X-ray crystallography.29 In fact, although the structures of
several ICK peptides have been determined using NMR, to
date only one ICK spider-venom toxin, ceratotoxin (CcoTx-I)
has been successfully characterized by X-ray crystallography
(PDB ID: 5EPM);29 moreover, in this structure, the target
peptide was bound to a speciﬁcally generated high-aﬃnity
antibody Fab fragment to aid crystallization. This work
represents the ﬁrst reported crystal structure of ProTx-II and,
to our knowledge, is the ﬁrst crystal structure of any unbound
ICK peptide toxin from spider venom.
A sample of ProTx-II known to be active against Nav1.7 was
crystallized, and the crystal diﬀracted well under synchrotron
conditions. The atomic resolution structure (0.99 Å)
corroborates many features of the previously published
structure solved by NMR (PDB ID: 2N9T).35 The disulﬁde
bonds can be clearly resolved in the electron density, with the
peptide showing the expected ICK fold and disulﬁde bond
arrangement (1-4, 2-5, 3-6), together with a largely rigid and
hydrophobic central core and more conformationally labile C-
and N-termini. The RMSD for the full-length peptide all-atom/
Cα = 3.19 Å/2.07 Å, whereas with the N- and C-termini
removed the RMSD are all-atom/Cα = 2.26 Å /1.36 Å,
highlighting the fact that most of the variability in the structure
lies in the termini. In contrast to 2N9T, but consistent with
other ICK peptides whose structures have been determined,
our structure shows evidence of hydrogen bonding consistent
with a beta hairpin from residues 19 to 27. The overall fold is
similar to that reported in 2N9T, but with some deviations
around M6 and L23; these could be a true reﬂection of the
structure or represent the eﬀects of crystal packing.
Two conformations of the N-terminal Y1 were observed in
the electron density map. The crystal structure also shows the
same hydrogen-bond interactions between the side chains of
D10 and R13 seen in the NMR models (Figure 8), and a
hydrogen bond between the side chain of E3 and the backbone
of T8, which are not found in 2N9T. Further hydrogen bonds
between the peptide backbone atoms, notably E3-K14, C9-L23
and M6-C25 give greater stability to the overall fold.
Ultimately, the crystal structure provides conclusive proof
that the biologically active form of ProTx-II adopts the ICK
fold.
Figure 5. NanoESI spectra of (A) ProTx-II/24h and (B) ProTx-II/
7d peptides. The predominant charge states observed are +4 and +5
for the ProTx-II/24h and ProTx-II/7d, respectively. Peaks annotated
with * correspond to contaminant species.
Figure 6. Zoom-in of the +4 charge states of (A) ProTx-II/24h and
(B) ProTx-II/7d peptides and theoretical isotope distribution
corresponding to a ProTx-II with (C) all cysteines oxidized and (D)
all cysteines reduced.
Figure 7. Arrival time distribution (ATD) from the IM-MS analysis of
the +4 ion for (A) ProTx-II/24h and (B) ProTx-II/7d peptides. (C)
The corresponding mass spectrum for ProTx-II/24h and (D−F) mass
spectra corresponding to the diﬀerent colored ATD regions for
ProTx-II/7d.
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■ CONCLUSIONS
In this paper, we report the synthesis of three synthetic
analogues of the ICK scaﬀold spider toxin ProTx-II, where each
of the three disulﬁde bridges is regioselectively replaced by a
thioether linkage. Incorporation of orthogonally protected
(2R,6R)-lanthionine via solid-phase synthesis, followed by
selective deprotection and on-resin cyclization, has enabled us
to achieve for the ﬁrst time the synthesis of highly complex
triply bridged peptides with two cystine bridges and one
lanthionine bridge. Moreover, in this work we have also
demonstrated that very large lanthionine-bridged rings (up to
15 residues for peptide 14) can be synthesized by this
approach.
These lanthionine-bridged peptides have larger ring sizes
than those found in the naturally occurring lantibiotics,
demonstrating the power of this approach for designing and
synthesizing conformationally constrained peptides. It therefore
also enables another approach for the modiﬁcation of naturally
occurring spider venom toxins as leads for potent and selective
sodium channel blockers with good pharmacokinetic proper-
ties, complementary to the mutagenesis and chimeric peptide
approaches previously published.28,29,35,36,56
Although lanthionine- and selenolanthionine-bridged ana-
logues of other biologically active cyclic peptides have
previously been reported to maintain or increase potency and
stability relative to cystine-bridged peptides,18−20 this approach
was not successful in delivering potent or selective Nav1.7
channel blockers based on ProTx-II. This could result from a
number of factors: the shorter bridge between the α-carbons;
the diﬀerences between the geometrical constraints imposed by
a thioether versus a disulﬁde bridge; or diﬀerences in the
correct folding of the resulting peptide. Indeed, a recent NMR
study57 comparing thioether analogues of disulﬁde-bridged
cyclic peptides targeting Death Receptor 5 with cystine-bridged
peptides concluded that the thioether peptide was slightly less
folded than the disulﬁde peptide.
In this regard, we have also demonstrated the importance of
choosing the correct conditions for the oxidative folding of
complex peptide toxins. This step is currently a bottleneck in
the successful high-throughput production, and scale-up, of
peptides containing multiple disulﬁde bridges.58 For ProTx-II,
the presence of a redox buﬀer containing an excess of GSSG
and GSH appears to be mandatory for the formation of the
corrected folded toxin with all of the disulﬁde bridges formed
(ProTx-II/24h). Conversely, it is clear from our IM-MS
studies that aerial oxidation in water at neutral pH gives a
number of products (ProTx-II/7d), none of which is in the
fully oxidized state. Whether these partially cyclized peptides
Figure 8. (A) 2Fo-Fc Electron density map calculated using experimental phases, showing traceable peptide backbone and well-resolved side chains.
(B) Fragment of ProTx-II crystal structure showing hydrogen bonding between R13 and D10. (C) Comparison of the X-ray crystal structure (left)
with previously published NMR ensemble (PDB ID: 2N9T) showing similar overall folding and structure.
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result from the kinetic formation of one or more incorrect Cys-
Cys linkages, or whether they arise from an incorrectly folded
intermediate with one or more correct Cys-Cys linkages, is
impossible to determine in this case, as the observed ATD
distribution (Figure 7) could arise from diﬀering collision cross
sections of both incorrectly folded peptides and incomplete
disulﬁde oxidation.
This also raises the wider issue of whether the use of aerial
oxidation, rather than the GSSG/GSH buﬀer, for folding the
lanthionine hybrids 12, 13, and 14 may have been a
contributory factor to their lack of activity. An additional
complication is that the methodology that we have developed
for synthesizing these hybrids necessarily introduces a non-
reducible linkage during the synthesis. For multiply disulﬁde
bridged peptides and small proteins, it is widely accepted that
there are several diﬀerent pathways of oxidative folding. These
vary from one extreme in which an ensemble of heterogeneous
intermediates with many non-native disulﬁde bonds are initially
generated, with these rearranging over time via disulﬁde
shuﬄing to give the correctly folded and connected peptides,
to the other extreme in which the amino acid sequence dictates
a folding pathway which leads predominantly or exclusively to
native disulﬁde bonds without subsequent rearrangement being
necessary, with intermediate situations in which the formation
of a non-native bridge creates a correctly folded peptide in
which the required cysteine residues are brought into proximity,
allowing reshuﬄing to give the correct connectivity.59 More-
over, for some peptide sequences such as tick anticoagulant
peptide (TAP) it has also been shown that incorrectly folded/
connected intermediates can act as kinetic “traps”, giving highly
stable structures that are diﬃcult to refold/reconnect into the
correct structure.60 Thus, once a nonreducible lanthionine
bridge has been introduced during the synthesis of the linear
peptide, then the peptide may well have been trapped into a
non-natural fold from which it cannot easily refold/rearrange to
the native fold/connectivity.
Importantly, in this work we have also demonstrated the
power of IM-MS studies for rapidly determining whether the
oxidative folding method employed for synthetic ICK fold
toxins gives a single, correctly folded and oxidized peptide or a
mixture of incompletely oxidized species. We envisage that this
will be particularly useful when screening libraries of
peptides29,39 based on lead peptides from spider venoms.
Such libraries, whether produced by either solid-phase synthesis
or recombinant expression, usually rely on aerial oxidation to
form the disulﬁde bridges, and our present work suggests that
for some sequences in these libraries, a lack of biological activity
might result from misfolding or incomplete oxidation of the
particular peptide.
We have also reported here the ﬁrst crystal structure of an
ICK peptide toxin from spider venom not bound to a substrate.
Whereas the X-ray crystal structure of a much larger (278
residues) phospholipase D enzyme spider venom peptide has
recently been reported,61 smaller (30−35 residue) peptides
such as ProTx-II are surprisingly diﬃcult to crystallize. Hitherto
all structural studies with these ICK fold spider toxins have
been carried out using NMR techniques. The high resolution of
this X-ray crystal structure structure of ProTx-II has enabled
hydrogen bonds which could not be seen in the NMR
structures to be observed. In turn, this will shed additional light
on the stabilization of the ICK fold, and may help with further
analysis of the structure−activity relationships between these
toxins and the sodium channel receptors.
Finally, having demonstrated the potential of this solid-phase
peptide synthesis approach to the preparation of ICK fold
peptide toxin analogues with Cys-Cys linkages replaced by
unnatural bridges, this paves the way for the preparation of
other peptide structures with diﬀerent ring sizes and bridge
geometry. This opens up the potential for the design of more
potent and selective Nav1.7 channel blockers with better
pharmacokinetic properties and metabolic stability. In addition,
peptides with one side-chain bridge that is regioselectively
installed and cannot be reduced may also act as tools for
investigating the folding pathways of these multiply bridged
peptides, in combination with the IM-MS methodology
reported here. Although the presence of a nonreducible side-
chain bridge could be problematic for the correct folding of
some peptide sequences, conversely in some cases it also has
the potential to streamline the folding pathways by diminishing
the number of nonproductive conformations available10,58 and
thus improving the synthetic routes to these peptides.
■ EXPERIMENTAL SECTION
General Experimental for Peptide Synthesis. Protected amino
acids and coupling reagents were purchased from Novabiochem;
coupling reagents, bases, and solvents were purchased from Sigma-
Aldrich. All water used was either distilled using an Elga Purelab
Option R 7 water puriﬁer or used directly from a bottle of HPLC-
grade water. The peptides were either synthesized using an automated
peptide synthesizer or manually, using the same timings and solution
volumes. Amino acid and reagent concentrations were calculated based
on the quantity and loading of the resin. The total volume of all
reagents in each step was 1.5 mL. All reagents were dissolved in HPLC
grade DMF.
Microwave couplings were carried out using a Personal Chemistry
Smith Creator microwave loaded with 5 mL reaction vials. In all cases,
the vial was irradiated for 5 min at 60 °C and 300 W before transfer of
the resin back to the reaction syringe. DMF was used as the primary
solvent throughout the peptide synthesis.
Peptides were centrifuged using an Eppendorf Centrifuge, model
5810R, and were lyophilized using a Thermo Scientiﬁc Heto
PowerDry LL1500 freeze-dryer.
Automated Peptide Synthesis. Peptides were synthesized on a
MultiSynTech Syro Peptide Synthesizer (Model MP-60).
Manual Peptide Synthesis. All manual coupling and depro-
tection steps, and complete manual peptide syntheses, were carried out
using an IKA KS130 basic platform shaker to agitate the solutions.
Reactions were carried out in 5 mL syringes with frits, which were
evacuated by hand at the end of each reaction.
Fmoc Deprotection. For the automated peptide syntheses, all
Fmoc deprotections were carried out using a solution of 40%
piperidine in DMF, which was added to the syringe containing the
resin. The mixture was agitated for 20 s every minute for a total of 3
min before removal of reagent by ﬁltration under vacuum. The resin
was washed with DMF (4 × 1.5 mL) before addition of a second
portion of piperidine in DMF solution (40% v/v, 0.75 mL), followed
by DMF (0.75 mL) to make an overall 20% v/v solution of piperidine
in DMF. This mixture was agitated for 20 s every minute for a total of
10 min. The reagents were removed by ﬁltration under vacuum, and
the resin was washed with DMF (6 × 1.5 mL). For the manual peptide
syntheses, all Fmoc deprotections were carried out using a solution of
40% piperidine in DMF, which was added to the syringe containing
the resin. The mixture was agitated for 3 min before removal of
reagent by ﬁltration. A second portion of piperidine in DMF solution
(40% v/v, 0.75 mL) was added, followed by DMF (0.75 mL) to make
an overall 20% v/v solution of piperidine in DMF. This mixture was
agitated for a total of 10 min. The reagents were removed by ﬁltration,
and the resin was washed with DMF (6 × 1.5 mL).
Amino Acid Coupling. Fmoc-protected amino acid (4 equiv) was
added to the reaction syringe with HBTU (4 equiv) and DIPEA (8
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equiv). The mixture was agitated for 20 s every 3 min for a total of 40
min. The reagents were removed by ﬁltration under vacuum, and the
resin was washed with DMF (4 × 1.5 mL).
Lanthionine Coupling. (S)-Allyl 3-((S)-2-((9-ﬂuorenyl-
methoxycarbonyl)amino-3- tert-butoxy-3-oxopropylthio)-2-
(allyloxycarbonylamino)propanoic acid (1) (3 equiv), PyAOP (5
equiv), and HOAt (5 equiv) were dissolved in DMF (4 mL). To this,
N,N-diisopropylethylamine (10 equiv) was added and left to react for
1 min before addition to a microwave vial containing the resin. The
vial was irradiated for 5 min at 60 °C before transfer of the resin back
to the reaction syringe. The resin was then washed with DMF (4 × 1.5
mL).
Allyl/Alloc Deprotection. Simultaneous deprotection of both the
allyl and Alloc ester groups was performed using tetrakistriphenyl-
phosphine palladium(0) (1 equiv) and 1,3-dimethylbarbituric acid (10
equiv) in a 1:1 solution of CHCl3: DMF (2 mL). This was left to react
for 2 h in the dark under argon before removal of the solution by
ﬁltration. The resin was then washed with CH2Cl2 (10 × 1.5 mL),
sodium diethyldithiocarbamate (5% w/v, 15 × 1.5 mL), and DMF (10
× 1.5 mL).
Lanthionine Cyclization. N,N-Diisopropylethylamine (10 equiv)
was added to a solution of PyAOP (5 equiv) and HOAt (5 equiv) in
DMF (4 mL). The solution was left to react for 1 min before addition
to a microwave vial containing the resin. The vial was irradiated for 5
min at 60 °C before transfer of the resin back to the reaction syringe.
The resin was then washed with DMF (4 × 1.5 mL).
Cleavage from the Resin. Peptides were ﬁrst washed with DMF
(4 × 1.5 mL), CH2Cl2 (4 × 1.5 mL), methanol (4 × 1.5 mL), and
diethyl ether (4 × 1.5 mL) before drying in a desiccator for 45 min. A
solution of 94% TFA, 2.5% water, 2.5% EDT, and 1% TIPS (2.5 mL)
was then added to the resin and left to agitate for 30 min on the
platform shaker. After this time, the entire solution was transferred to a
Falcon tube, and 12 mL of diethyl ether was added to precipitate the
peptide. The cleavage procedure was then repeated with fresh cleavage
solution (2.5 mL containing 94% TFA, 2.5% water, 2.5% EDT, and 1%
TIPS) and left to agitate for a further 40 min. The entire solution was
again transferred to a Falcon tube before addition of 12 mL of diethyl
ether to precipitate the peptide.
The Falcon tubes were then centrifuged for 10 min at 4000 rpm and
4 °C before decanting oﬀ the diethyl ether solution. This process was
performed three times in total before re-dissolving the peptide in water
and lyophilizing.
HPLC Puriﬁcation. The peptides were analyzed and puriﬁed via
reverse phase HPLC using either a Varian ProStar system with a
model 210 solvent delivery module and a model 320 UV detector or a
Dionex system with a PDA-100 photodiode array detector and a
model ASI-100 automated sample injector. The preparative
puriﬁcation was performed using an ACE C8-300 semipreparative
column (150 × 10 mm, ﬂow rate of 8.0 mL/min), with UV detection
at 215 and 254 nm, loaded with 200−1850 μL aliquots of a 10−20
mg/mL solution of peptide dissolved in water. Gradient conditions are
reported for each peptide. The fractions containing the correct peak
were pooled, the solvent was removed under reduced pressure to
approximately 2 mL, and the solution was freeze-dried.
HPLC Analysis. All peptides were analyzed using UV detection at
215 and 254 nm, using the conditions shown below. Retention times
are reported for each peptide.
HPLC Method A. ACE C8-300 analytical column (150 × 10 mm,
ﬂow rate of 1.0 mL/min). Gradient: 2−98% B over 20 min (A = water,
B = acetonitrile, 0.1% TFA).
HPLC Method B. Dr Maisch C8 column (Reprosil Gold 200 C8, 5
μm, 250 × 4.6 mm, ﬂow rate of 1.0 mL min−1). Gradient: 0−2 min on
95% A; then 5−95% B over 48 min; then 95% B over 2 min; then 95−
5% B over 3 min; then 5% B over 5 min (A = water, B = acetonitrile,
0.1% TFA).
ESI-MS Analysis. This was performed on a Waters Acquity Ultra
Performance LC/MS machine using a linear gradient of 5−95% B over
5 min (A = water, B = acetonitrile, 0.1% TFA). The analysis of the
chromatograms was conducted using MassLynx software version 4.0.
Single Ring Thioether Analogue 2a. The synthesis was carried
out on a 100 mg scale using preloaded Fmoc-Lys(Boc)-NovaSyn resin
(loading 0.24 mmol/g). The following protected amino acids were
used: Fmoc-Glu(OtBu)-OH; Fmoc-Gly-OH; Fmoc-Lys(Boc)-OH;
Fmoc-Leu-OH; Fmoc-Met-OH: Fmoc-Arg(Pbf)-OH; Fmoc-Val-OH;
Fmoc-Trp(Boc)-OH. The peptide was assembled following the
strategy outlined in Scheme 1. Amino acid coupling steps, Fmoc
deprotection, coupling of lanthionine 1, removal of the allyl/Aloc
groups, and cyclization were all carried out according to the general
procedures above. The peptide was cleaved under standard conditions,
washed with ether, and lyophilized. The peptide was puriﬁed by
semipreparative HPLC using a gradient of 5−50% B over 15 min (A =
water, B = acetonitrile) to yield 3 mg of product (8%). m/z (ES+)
855.66 ([M + 2H]2+), 570.68 ([M + 3H]3+), 428.23 ([M + 4H]4+).
HPLC Method A: tR = 6.9 min.
Single Ring Thioether Analogue 3a. The synthesis was carried
out on a 100 mg scale using preloaded Fmoc-Trp(Boc)-NovaSyn resin
(loading 0.20 mmol/g). The following protected amino acids were
used: Fmoc-Glu(OtBu)-OH; Fmoc-Lys(Boc)-OH; Fmoc-Leu-OH;
Fmoc-Met-OH: Fmoc-Arg(Pbf)-OH; Fmoc-Val-OH; Fmoc-Trp-
(Boc)-OH. The following Hmb-protected amino acids were also
incorporated: Fmoc-(FmocHmb)-Gly-OH (position 5); Fmoc-
(FmocHmb)-Leu-OH (position 10); Fmoc-(FmocHmb)-Lys(Boc)-
OH (position 15). The peptide was assembled following the strategy
outlined in Scheme 1. Amino acid coupling steps, Fmoc deprotection,
coupling of lanthionine 1, removal of the allyl/Aloc groups, and
cyclization were all carried out according to the general procedures
above. The peptide was cleaved under standard conditions, washed
with ether, and lyophilized. The peptide was puriﬁed by semi-
preparative HPLC using a gradient of 10−55% B over 8 min (A =
water, B = acetonitrile) to yield 4 mg of product (9%). m/z (ES+)
538.27 ([M + 4H]4+). HPLC Method A: tR = 2.4 min.
Single Ring Thioether Analogue 4a. The synthesis was carried
out on a 100 mg scale using preloaded Fmoc-Trp(Boc)-NovaSyn resin
(loading 0.20 mmol/g). The following protected amino acids were
used: Fmoc-Asp(OtBu)-OH; Fmoc-Glu(OtBu)-OH; Fmoc-Gly-OH;
Fmoc-Lys(Boc)-OH; Fmoc-Leu-OH; Fmoc-Met-OH: Fmoc-Arg-
(Pbf)-OH; Fmoc-Ser(tBu)-OH; Fmoc-Thr(tBu)-OH; Fmoc-Val-OH;
Fmoc-Trp(Boc)−OH. The peptide was assembled following the
strategy outlined in Scheme 1. Amino acid coupling steps, Fmoc
deprotection, coupling of lanthionine 1, removal of the allyl/Aloc
groups, and cyclization were all carried out according to the general
procedures above. The peptide was cleaved under standard conditions,
washed with ether, and lyophilized. The peptide was puriﬁed by
semipreparative HPLC using a gradient of 5−50% B over 15 min (A =
water, B = acetonitrile) to yield 0.5 mg of product (1%). m/z (ES+)
1021.71 ([M + 2H]2+). HPLC Method A: tR = 2.6 min.
Full-Length C-Terminal Thioether Analogue 12. The synthesis
was carried out on a 100 mg scale using preloaded Fmoc-Trp(Boc)-
NovaSyn resin (loading 0.20 mmol/g). The following protected amino
acids were used: Fmoc-Cys(Trt)-OH; Fmoc-Asp(OtBu)-OH; Fmoc-
Glu(OtBu)-OH; Fmoc-Lys(Boc)-OH; Fmoc-Leu-OH; Fmoc-Met-
OH: Fmoc-Gln(Trt)-OH; Fmoc-Arg(Pbf)-OH; Fmoc-Ser(tBu)-OH;
Fmoc-Thr(tBu)-OH; Fmoc-Val-OH; Fmoc-Trp(Boc)-OH; Fmoc-
Tyr(tBu)-OH. The following Hmb-protected amino acids were also
incorporated: Fmoc-(FmocHmb)-Lys(Boc)-OH (positions 4, 14, 28);
Fmoc-(FmocHmb)-Gly-OH (position 18); Fmoc-(FmocHmb)-Leu-
OH (position 23). The peptide was assembled following the strategy
outlined in Scheme 2. Amino acid coupling steps, Fmoc deprotection,
coupling of lanthionine 1, removal of the allyl/Aloc groups, and
cyclization were all carried out according to the general procedures
above. The peptide was cleaved from the resin using a solution of
96.5% TFA, 2.5% water, and 1% TIPS (2.5 mL) and left to stir for 1 h.
After this time, the entire solution was transferred to a Falcon tube,
and 12 mL of diethyl ether was added to precipitate the peptide. The
Falcon tube was then centrifuged for 10 min at 4000 rpm and 4 °C
before decanting oﬀ the diethyl ether solution. This process was
performed three times in total before re-dissolving the peptide in water
and lyophilizing. The peptide was puriﬁed by semipreparative HPLC
using a gradient of 10−55% B over 15 min (A = water, B =
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acetonitrile, 0.1% TFA) to yield 0.3 mg of product (0.4%). m/z (ES+)
758.50 ([M + 5H]5+). HPLC Method B: tR = 19.16 min.
Full-Length Middle Ring Thioether Analogue 13. The
synthesis was carried out on a 100 mg scale using preloaded Fmoc-
Trp(Boc)-NovaSyn resin (loading 0.20 mmol/g). The following
protected amino acids were used: Fmoc-Cys(Trt)-OH (positions 15,
25); Fmoc-Cys(S(Tmp))-OH (positions 2, 16); Fmoc-Asp(OtBu)-
OH; Fmoc-Glu(OtBu)-OH; Fmoc-Lys(Boc)-OH; Fmoc-Leu-OH;
Fmoc-Met-OH: Fmoc-Gln(Trt)-OH; Fmoc-Arg(Pbf)-OH; Fmoc-
Ser(tBu)-OH; Fmoc-Thr(tBu)-OH; Fmoc-Val-OH; Fmoc-Trp(Boc)-
OH; Fmoc-Tyr(tBu)−OH. The following Hmb-protected amino acids
were also incorporated: Fmoc-(FmocHmb)-Lys(Boc)-OH (positions
4, 14, 28); Fmoc-(FmocHmb)-Gly-OH (position 18); Fmoc-
(FmocHmb)-Leu-OH (position 23). The peptide was assembled
following the strategy outlined in Scheme 3. Amino acid coupling
steps, Fmoc deprotection, coupling of lanthionine 1, removal of the
allyl/Aloc groups, and cyclization were all carried out according to the
general procedures above. Selective deprotection of the S(Tmp)
groups from the orthogonally protected cysteine residues was carried
out using 5% DTT in 0.1 M NMM in DMF (1.5 mL) (3 × 30 min)
before washing with DMF (4 × 1.5 mL). The deprotected cysteines
were then cyclized using N-chlorosuccinimide (53.4 mg, 2 equiv) in
DMF (2 mL) for 1.5 h before again washing with DMF (4 × 1.5 mL).
The peptide was cleaved from the resin using a solution of 96.5% TFA,
2.5% water, and 1% TIPS (2.5 mL) and left to stir for 1 h. After this
time, the entire solution was transferred to a Falcon tube, and 12 mL
of diethyl ether was added to precipitate the peptide. The Falcon tube
was then centrifuged for 10 min at 4000 rpm and 4 °C before
decanting oﬀ the diethyl ether solution. This process was performed
three times in total before re-dissolving the peptide in water and
lyophilizing. The peptide was puriﬁed by semipreparative HPLC using
a gradient of 10−55% B over 15 min (A = water, B = acetonitrile, 0.1%
TFA) to yield 5 mg of product (7%). This was then dissolved in water
(pH 7.7) at 1 mg/10 mL concentration, stirred for a further 11 days at
4 °C to ensure complete disulﬁde bond formation, then lyophilized.
m/z (ES+) 544.64 ([M + 7H]7+). HPLC Method B: tR = 19.15 min.
Full-Length N-Terminal Thioether Analogue 14. The synthesis
was carried out on a 100 mg scale using preloaded Fmoc-Trp(Boc)-
NovaSyn resin (loading 0.20 mmol/g). The following protected amino
acids were used: Fmoc-Cys(Trt)-OH; Fmoc-Asp(OtBu)-OH; Fmoc-
Glu(OtBu)-OH; Fmoc-Lys(Boc)-OH; Fmoc-Leu-OH; Fmoc-Met-
OH: Fmoc-Gln(Trt)-OH; Fmoc-Arg(Pbf)-OH; Fmoc-Ser(tBu)-OH;
Fmoc-Thr(tBu)-OH; Fmoc-Val-OH; Fmoc-Trp(Boc)-OH; Fmoc-
Tyr(tBu)-OH. The following Hmb-protected amino acids were also
incorporated: Fmoc-(FmocHmb)-Lys(Boc)-OH (positions 4, 14, 28);
Fmoc-(FmocHmb)-Gly-OH (position 18); Fmoc-(FmocHmb)-Leu-
OH (position 23). The peptide was assembled following the general
strategy outlined in Scheme 2, but with the protected lanthionine 1
incorporated at position 16 and cyclized at position 2. Amino acid
coupling steps, Fmoc deprotection, coupling of lanthionine 1, removal
of the allyl/Aloc groups, and cyclization were all carried out according
to the general procedures above. The peptide was cleaved from the
resin using a solution of 96.5% TFA, 2.5% water, and 1% TIPS (2.5
mL) and left to stir for 1 h. After this time, the entire solution was
transferred to a Falcon tube, and 12 mL of diethyl ether was added to
precipitate the peptide. The Falcon tube was then centrifuged for 10
min at 4000 rpm and 4 °C before decanting oﬀ the diethyl ether
solution. This process was performed three times in total before re-
dissolving the peptide in water and lyophilizing. The peptide was
puriﬁed by semipreparative HPLC using a gradient of 10−55% B over
15 min (A = water, B = acetonitrile, 0.1% TFA) to yield 0.8 mg of
product (1%). m/z (ES+) 544.64 ([M + 7H]7+). HPLC Method B: tR
= 19.11 min.
Synthesis of ProTx-II. The synthesis was carried out on a 100 mg
scale using preloaded Fmoc-Trp(Boc)-NovaSyn resin (loading 0.20
mmol/g). The following protected amino acids were used: Fmoc-
Cys(Trt)-OH, Fmoc-Asp(OtBu)-OH; Fmoc-Glu(OtBu)-OH; Fmoc-
Gly-OH; Fmoc-Lys(Boc)-OH; Fmoc-Leu-OH; Fmoc-Met-OH:
Fmoc-Gln(Trt)-OH; Fmoc-Arg(Pbf)-OH; Fmoc-Ser(tBu)-OH;
Fmoc-Thr(tBu)-OH; Fmoc-Val-OH; Fmoc-Trp(Boc)-OH; Fmoc-
Tyr(tBu)-OH. Amino acid coupling steps and Fmoc deprotection
were all carried out according to the general procedures above. The
peptide was cleaved under standard conditions, washed with ether, and
lyophilized.
ProTx-II/7d. The crude peptide was puriﬁed using a gradient of
35−60% B over 15 min (A = water, B = acetonitrile, 0.1% TFA) to
give the linear peptide: m/z (ES+) 765.93 ([M + 5H]5+), 639.57 ([M
+ 6H]6+. Analytical HPLC: tR = 2.4 min. The peptide was then allowed
to cyclize for 7 days in pure water at 4 °C and a concentration of 0.1
mg/mL. The solution was then concentrated to approximately 2 mL,
ﬂash frozen, and lyophilized to yield the cyclized peptide as a white
solid (10 mg, 13%) m/z (ES+) 1276.51 ([M + 3H]3+), 957.43 ([M +
4H]4+), 765.93 ([M + 5H]5+), 638.72 ([M + 6H]6+). HPLC Method
B: tR = 21.80 min.
ProTx-II/24h. Glutathione (0.15 mM) and glutathione disulﬁde
(0.3 mM) were added to a mixture of urea (2 M) and Tris-HCl (0.1
M) in water. The pH was adjusted to 8.0 using saturated aqueous
sodium bicarbonate. A solution of crude linear ProTx-II was added at a
concentration of 0.1 mg/mL and left to stir for 24 h at room
temperature. After this time, the pH of the solution was adjusted to
pH 3 using HCl (2 M). The peptide was puriﬁed by semipreparative
HPLC: gradient: 0−1.5 min on 95% A; then 5−70% B over 38 min;
then 70% B over 2.0 min; then 70−5% B over 1.1 min; then 5% B over
2.4 min (A = water, B = acetonitrile, 0.1% TFA). The peptide was
further puriﬁed using analytical HPLC Method B: tR = 21.03 min.
Automated and Manual Patch Clamp Assays. Peptides were
diluted to a concentration of 100 nM and tested against stably
transfected cell lines expressing the hNav1.7 receptor. Peptides 2a, 2b,
4a, 4b, 5b, 12, 13, 14, ProTx-II/7d, Sigma, and Smartox were tested
against stably transfected cell lines expressing the hNav1.7 receptor,
using the hNav1.7-HEK cell IonWorks Population Patch Clamp Assay,
as designed by Essen Bioscience. These peptides were tested at 11
diﬀerent points to make an IC50 curve using 3-fold dilution from 1
μM to 0.000001 μM in triplicate, using tetracaine as the control
molecule. The samples were allowed to incubate for 5−7 min before
testing occurred and were tested in the presence of 0.1% bovine serum
albumin to prevent the samples adhering to the side of the microtiter
plate. The percentage inhibition between the ﬁrst and 20th pulses was
then analyzed and plotted on a graph. Peptides 3a, 3b, 14, ProTx-II/
24h, ProTx-II/7d, Sigma, Smartox, and the linear sequence of ProTx-
II were tested using the QPatch Patch Clamp Assay as designed by
B’SYS GmbH. hNav1.7 inward peak currents were recorded in CHO
cells stably transfected with cDNA encoding this sodium channel in
the resting, fast and slow inactivated state. Lidocaine was used as the
reference. Full details of these experiments are in the Supporting
Information.
HPLC Analysis of ProTx-II Samples. ProTx-II samples were
mixed as indicated and co-injected into a Dr Maisch C8 column,
eluting with HPLC Method B.
NanoESI and IM-MS Analyses. All measurements were carried
out using a G2Si mass spectrometer (Waters, UK). The TOF analyzer
was operated in V-optic mode and tuned for an operating resolution of
20 000 fwhm. The instrument was mass calibrated using a 2 mg/mL
solution of CsI. ProTx-II samples were dissolved in 50% MeOH with
0.1% HCOOH and 2.5 μL aliquots, of 10 μM concentration, were
delivered to the mass spectrometer by means of nanoESI using gold-
coated capillaries, prepared in house. Instrumental parameters were as
follows unless otherwise speciﬁed: capillary voltage 0.9 kV, cone
voltage 40 V, trap energy 4 V, transfer energy 2 V, bias voltage 45 V,
IMS pressure 3 mbar, IMS wave velocity 650 m/s, IMS wave height 35
V. Data acquisition, processing, and calculation of theoretical isotopic
distributions were carried out using MassLynx (v4.1) software (Waters
Corp., Milford, MA). IM-MS data were processed in Driftscope v2.8
and exported for further analysis to MassLynx.
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X-ray crystal structure of ProTx-II has been deposited in the
Protein Data Bank with accession code 5O0U.
X-ray crystallographic data for ProTx-II (CIF)
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clamp assays (PDF)
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